KR910011240A - Pharmaceutical formulations of the eye and treatment methods using the same - Google Patents

Abstract

No content

Description

Pharmaceutical formulations of the eye and treatment methods using the same

As this is a public information case, the full text was not included.

Claims (12)

A pharmaceutical formulation composition consisting of a basic active ingredient, a mucomimetic polymer of anionic mucus and a cation exchange resin and controlling or lowering intraocular pressure. The pharmaceutical preparation composition of the eye according to claim 1, wherein the fruit preparation composition is an aliquot. The pharmaceutical formulation of the eye according to claim 1, wherein the pharmaceutical formulation of the sustained eye is in the form of a liquefied gel, a fluid dispersion and an anhydrous salt, and a betabroker having the structural formula described below while controlling or lowering intraocular pressure is provided in a therapeutically useful amount. Pharmaceutical formulation of the eye, characterized in that consisting of. R ¹ -O-CH ₂ -CH (OH) -CH ₂ -NR ² R ³ where R ¹ is a substituted or unsubstituted cyclic or aliphatic monomer, R ² and R ³ are H and a substituted or unsubstituted alkyl The independent polymers of anionic mucus have a carboxylic acid applicator having 2 to 7 carbon atoms per functional group, have a molecular weight of 50,000 to 6 million, and have a viscosity of about 1 in the form of a liquefied gel or fluid dispersion. ˜20,000, specific cation exchange resin concentration of about 0.05 wt% to 10.0 wt%, pH of the composition is about 3.0 to 8.5. 4. The pharmaceutical formulation of the eye according to claim 3, wherein the specific cation exchange resin is in the form of finely divided powder and the powder is composed of spherical particles. 5. The pharmaceutical formulation of the eye according to claim 4, wherein the cation exchange resin is sodium poly (styrene divinylbenzene) sulfonic acid and the betablocker is betasolol. The method according to claim 3, wherein the beta blocker is present at a concentration of about 0.25wt%, the negative polymer of the anionic mucus is present at a concentration of about 0.2wt%, and the cation exchange resin is present at a concentration of about 0.25wt%. Pharmaceutical formulation of the eye. A pharmaceutical formulation composition for the eye, comprising an active ingredient, an anionic mucus polymer, a finely divided cation exchange resin, and controlling or lowering intraocular pressure. 8. The pharmaceutical formulation of the eye according to claim 7, wherein said basic active ingredient is betasolol. 8. The pharmaceutical formulation of the eye according to claim 7, wherein the basic active ingredient is Timo. The method of claim 7, wherein the active ingredient is pilocarpine (pilocarpine), epinephrine (epinephrine), proepinephrine (proepinephrine), norepinephrine, pronorepinephrine (pronorepinephrine), clonldine para-amino Selected from p-aminoclonidine, para-acetoamidoclonidine or betasolol, timolol, acebutolol, alprenolol, atenolol, bevantolol , Bucomolol, buprenolol, bpranolol, butidrine, butitolol, bunitolol, bunolol, butocrolol, butamine, butazol, carazlol ), Carteolol, esaprolol, indenolol, indenolol, iprocrolol, labetolol, mepindolol, metipranolol , Metaprolol, maprolol, nadolol, nifenalol, ox Oxprenolol, pamatolol, paragolol, paragolol, penbutolol, pindolol, practolol, procinolol, pronetaro (pronethalol), proprenolol, sotalol, tazolol, thizolol, tiprenolol, tolamorol, toliprolol, befunolol, Esmalol, hepunolol, celiprolol, azotinolol, azotinolol, diacetalol, acebutolol, salbutanol and salbutanol and isosapro Pharmaceutical formulation for the eye, characterized in that the beta blocker selected from the roll (isoxaprolol). The method of claim 1, wherein the intraocular pressure is controlled and lowered using the composition of claim 1. According to claim 11, wherein the composition is a dispersion, finely dispersed cation exchange resin, the basic active ingredient is pilocarpine (pilocarpine), epinephrine (epinephrine), pronorepine phrine, norepinephrine (norepinephrine), pronorpinephrine (pronorepinephrine), clonldine, para-aminoclonidine, p-acetoamidoclonidine, or betasolol, timolol, acebutolol, alpreno Alprenolol, atenolol, bevantolol, bucomolol, bucomolol, bupranolol, butidrine, butitolol, bunitolol, bunolol, butokerolol (butocrolol), butamine (butamine), butocrolol (butocrolol), butamine (butamine), carazolol (carazolol), carteolol (carteolol), esaprolol (inaprolol), indenolol (ifenol) Icrocrolol, Labetolol, Mepinalol ol), metipranolol, metaprolol, moprolol, nadolol, nifenalol, oxprenolol, pamatolol, paragolol (paragolol), penbutolol, pendolol, pindolol, practolol, procinolol, sotalol, tazolol, and tiprenolol Tolamorol, toliprolol, toliprolol, befunolol, esmalol, hepunolol, nepunolol, celiprolol, azotinolol, azotinolol, diacetalol (diacetalol), acebutolol (acebutolol), salbutanol (salbutanol) and isosaprolol (isoxaprolol) is a beta blocker characterized in that the treatment method. ※ Note: The disclosure is based on the initial application.